SCHEDULE 13G: Venrock Entities Disclose 7.7% Passive Stake in ORIC Pharmaceuticals Following Private Placement
Beneficial Ownership Report
A group of Venrock entities, including Venrock Healthcare Capital Partners III, L.P., has disclosed a 7.7% beneficial ownership stake in ORIC Pharmaceuticals, Inc., primarily through a recent private placement.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The Reporting Persons collectively beneficially own 6,596,885 shares of Common Stock of ORIC Pharmaceuticals, Inc.
- This aggregate ownership represents 7.7% of ORIC Pharmaceuticals' outstanding common stock.
- The ownership is based on an estimated 85,218,393 shares of common stock outstanding as of May 29, 2025.
- This total includes 71,088,080 shares outstanding as of April 28, 2025, and an additional 14,130,313 shares issued upon the closing of a private placement on May 29, 2025.
- The Reporting Persons hold shared voting and shared dispositive power over all 6,596,885 shares.
- The filing indicates that the securities were not acquired for the purpose of changing or influencing the control of ORIC Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: The document is a factual, compliance-oriented SEC filing (Schedule 13G) reporting beneficial ownership. It contains no subjective language, forward-looking statements, or performance metrics that would indicate a positive or negative sentiment.
Future Outlook
NA
Industry Context
This filing reflects a significant investment by a healthcare-focused capital firm in a pharmaceutical company, which is a common occurrence in the biotechnology and pharmaceutical sectors where venture capital and private equity firms often take substantial stakes to support drug development and commercialization.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/08/2025 | Date of event which required the filing of this statement (crossing the 5% beneficial ownership threshold). |
| 04/28/2025 | Date as of which 71,088,080 shares of common stock were outstanding, as disclosed in ORIC Pharmaceuticals' Form 10-Q. |
| 05/05/2025 | Date ORIC Pharmaceuticals' Quarterly Report on Form 10-Q was filed with the SEC. |
| 05/29/2025 | Date of the closing of a private placement, resulting in the issuance of 14,130,313 additional shares of common stock. |
| 05/30/2025 | Date the Schedule 13G, Power of Attorney documents, and Joint Filing Agreement were executed and filed. |
Keywords
ORIC Pharmaceuticals, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, Private Placement, Institutional Investment, SEC Filing, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.